{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:43:30Z","timestamp":1780393410019,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11126-020-09877-5","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T04:20:35Z","timestamp":1609647635000},"page":"935-945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study"],"prefix":"10.1007","volume":"92","author":[{"given":"Jia-Wu","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Rong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Zheng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reng-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"9877_CR1","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3109\/00048674.2010.495940","volume":"44","author":"JH Kim","year":"2010","unstructured":"Kim JH, Byun HJ, Ann JH, Lee J. Relationship between subjective experiences and psychopathological dimensions in schizophrenia. Aust N Z J Psychiatry. 2010;44:952\u20137.","journal-title":"Aust N Z J Psychiatry"},{"key":"9877_CR2","doi-asserted-by":"publisher","first-page":"e83774","DOI":"10.1371\/journal.pone.0083774","volume":"8","author":"W Sellwood","year":"2013","unstructured":"Sellwood W, Morrison AP, Beck R, Heffernan S, Law H, Bentall RP. Subjective cognitive complaints in schizophrenia: relation to antipsychotic medication dose, actual cognitive performance, insight and symptoms. PLoS One. 2013;8:e83774.","journal-title":"PLoS One"},{"key":"9877_CR3","doi-asserted-by":"crossref","unstructured":"Naber D. Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiologia e Psichiatria Sociale. 2008;17:174\u20136.","DOI":"10.1017\/S1121189X00001238"},{"key":"9877_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0010-440X(03)00086-5","volume":"44","author":"E Stip","year":"2003","unstructured":"Stip E, Caron J, Renaud S, Pampoulova T, Lecomte Y. Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. Compr Psychiatry. 2003;44:331\u201340.","journal-title":"Compr Psychiatry"},{"key":"9877_CR5","doi-asserted-by":"crossref","unstructured":"Homayoun S, Nadeau-Marcotte F, Luck D, Stip E. Subjective and objective cognitive dysfunction in schizophrenia - is there a link? Front Psychol. 2011;2:1\u20138.","DOI":"10.3389\/fpsyg.2011.00148"},{"key":"9877_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.schres.2003.08.011","volume":"69","author":"A Prouteau","year":"2004","unstructured":"Prouteau A, Verdoux H, Briand C, Lesage A, Lalonde P, Nicole L, et al. Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res. 2004;69:85\u201391.","journal-title":"Schizophr Res"},{"key":"9877_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.psychres.2004.07.005","volume":"129","author":"A Prouteau","year":"2004","unstructured":"Prouteau A, Verdoux H, Briand C, Lesage A, Lalonde P, Nicole L, et al. The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Res. 2004;129:171\u20137.","journal-title":"Psychiatry Res"},{"key":"9877_CR8","doi-asserted-by":"crossref","unstructured":"Petersen L, Thorup A, Oqhlenschlaeger J, Christensen TO, Jeppesen P, Krarup G, et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the opus trial. Canadian J Psychiatry. 2008;53:660\u201370.","DOI":"10.1177\/070674370805301005"},{"key":"9877_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.eurpsy.2009.09.001","volume":"25","author":"M Lambert","year":"2010","unstructured":"Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psych. 2010;25:220\u20139.","journal-title":"Eur Psych"},{"key":"9877_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.euroneuro.2010.10.003","volume":"21","author":"R Schennach-Wolff","year":"2011","unstructured":"Schennach-Wolff R, Jaeger M, Mayr A, Meyer S, Kuehn K-U, Klingberg S, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients - is it all about early response? Eur Neuropsychopharmacol. 2011;21:370\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"key":"9877_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/NDT.S201726","volume":"15","author":"G Cerveri","year":"2019","unstructured":"Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"9877_CR12","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1017\/S1461145704004109","volume":"7","author":"S Leucht","year":"2004","unstructured":"Leucht S. Amisulpride - a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2004;7:S15\u201320.","journal-title":"Int J Neuropsychopharmacol"},{"key":"9877_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/acps.12526","volume":"133","author":"SD Ostergaard","year":"2016","unstructured":"Ostergaard SD, Lemming OM, Mors O, Correll CU, Bech P. Panss-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand. 2016;133:436\u201344.","journal-title":"Acta Psychiatr Scand"},{"key":"9877_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr. 2005;162:441\u20139.","journal-title":"Am J Psychiatr"},{"key":"9877_CR15","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/npp.2015.52","volume":"40","author":"AR Mahableshwarkar","year":"2015","unstructured":"Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40:2025\u201337.","journal-title":"Neuropsychopharmacology"},{"key":"9877_CR16","first-page":"646","volume":"80","author":"G Huber","year":"1989","unstructured":"Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med. 1989;80:646\u201352.","journal-title":"Recenti Prog Med"},{"key":"9877_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1053\/comp.2001.23144","volume":"42","author":"S Moritz","year":"2001","unstructured":"Moritz S, Lambert M, Andresen B, Bothern A, Naber D, Krausz M. Subjective cognitive dysfunction in first-episode and chronic schizophrenic patients. Compr Psychiatry. 2001;42:213\u20136.","journal-title":"Compr Psychiatry"},{"key":"9877_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","volume":"5","author":"RS Kahn","year":"2018","unstructured":"Kahn RS, van Rossum IW, Leucht S, McGuire P, Lewis SW, Leboyer M, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (optimise): a three-phase switching study. Lancet Psychiatry. 2018;5:797\u2013807.","journal-title":"Lancet Psychiatry"},{"key":"9877_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/schbul\/sbx076","volume":"44","author":"SD Ostergaard","year":"2018","unstructured":"Ostergaard SD, Foldager L, Mors O, Bech P, Correll CU. The validity and sensitivity of panss-6 in the clinical antipsychotic trials of intervention effectiveness (catie) study. Schizophr Bull. 2018;44:453\u201362.","journal-title":"Schizophr Bull"},{"key":"9877_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.comppsych.2010.12.008","volume":"52","author":"I Johnson","year":"2011","unstructured":"Johnson I, Tabbane K, Dellagi L, Kebir O. Self-perceived cognitive functioning does not correlate with objective measures of cognition in schizophrenia. Compr Psychiatry. 2011;52:688\u201392.","journal-title":"Compr Psychiatry"},{"key":"9877_CR21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/hup.1246","volume":"26","author":"YM Ahn","year":"2011","unstructured":"Ahn YM, Lee KY, Kim C-E, Kang D-Y, Seok J-H, Shin YM, et al. The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study. Hum Psychopharmacol Clin Exp. 2011;26:568\u201377.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"9877_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"9877_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/schbul\/sby095","volume":"45","author":"MT Samara","year":"2019","unstructured":"Samara MT, Nikolakopoulou A, Salanti G, Leucht S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45:639\u201346.","journal-title":"Schizophr Bull"},{"key":"9877_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/JCP.0b013e3181d2193c","volume":"30","author":"EM Derks","year":"2010","unstructured":"Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS, Grp ES. Antipsychotic drug treatment in first-episode psychosis should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol. 2010;30:176\u201380.","journal-title":"J Clin Psychopharmacol"},{"key":"9877_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.schres.2012.08.030","volume":"141","author":"SZ Levine","year":"2012","unstructured":"Levine SZ, Leucht S. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia. Schizophr Res. 2012;141:168\u201372.","journal-title":"Schizophr Res"},{"key":"9877_CR26","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.4088\/JCP.v67n1106","volume":"67","author":"R Emsley","year":"2006","unstructured":"Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJH, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psych. 2006;67:1707\u201312.","journal-title":"J Clin Psych"},{"key":"9877_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/appy.12238","volume":"8","author":"Y Liang","year":"2016","unstructured":"Liang Y, Cao C, Zhu C, Wang C, Zhang C, Dong F, et al. The effectiveness and safety of amisulpride in chinese patients with schizophrenia: an 8-week, prospective, open-label, multicenter, single-arm study. Asia Pac Psychiatry. 2016;8:241\u20134.","journal-title":"Asia Pac Psychiatry"},{"key":"9877_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/DHPS.S6226","volume":"2","author":"MF Juruena","year":"2010","unstructured":"Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug, healthcare and patient safety. 2010;2:205\u201311.","journal-title":"Drug, healthcare and patient safety"},{"key":"9877_CR29","unstructured":"Kopecek M, Bares M, Horacek J. Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride. Neuroendocrinol Lett. 2005;26:320\u20130."},{"key":"9877_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pnpbp.2006.07.006","volume":"31","author":"T Paparrigopoulos","year":"2007","unstructured":"Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:92\u20136.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-020-09877-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11126-020-09877-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-020-09877-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:18:52Z","timestamp":1629454732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11126-020-09877-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["9877"],"URL":"https:\/\/doi.org\/10.1007\/s11126-020-09877-5","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"13 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All participants provided written informed consent before enrollment in this study, which was approved by the ethics committee according to local legislation and conducted following the most recent version of the Declaration of Helsinki. The ethics committee belongs to Fuzhou Neuropsychiatric Hospital Affiliated to Fujian Medical University, China.We are in compliance with ethical standards and ethical considerations as specified per journal guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study was approved by the ethics committee belongs to Fuzhou Neuropsychiatric Hospital Affiliated to Fujian Medical University, China..","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants"}},{"value":"All participants gave their free and informed consent in writing to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for Publication(Include Appropriate Statements)"}},{"value":"None of the authors listed above have any conflicts of interest to report.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing Interests\/Conflict of Interest(Include Appropriate Disclosures)"}}]}}